This month saw the PTAB issue the final decision on a Kyle Bass inter partes review. Michael Loney asks whether that’s the last we’ll see of Bass at the Board and analyses the legacy of his campaign against pharmaceutical patents
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
A counterfeiting crackdown targeting fake FIFA World Cup merchandise and new partner hires by CMS, HGF and Winston Strawn were also among the top talking points
Abbott winning another round against Sinocare and Menarini, and 'long arm' clarification on the UK's position within the UPC, were also among major developments